Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Among individuals who still experienced symptomatic infections, those who received casirivimab and imdevimab were able to clear the virus faster and had much shorter symptom durationIn a cohort of...
-
EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)OCREVUS data show its consistent benefit on slowing disease progression in...
-
Anti-p53 antibodies are antibodies that mistakenly target a patient's own tissues, leading to a growth of solid tumors. Screening for Anti-p53 helps to diagnose throat, bowel and breast cancers...
-
The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patientsClear and quick...
-
Evrysdi has proven efficacy in adults, children and babies two months and older, as shown in two pivotal clinical trials Roche is actively engaging with health authorities in the EU to achieve broad...
-
Recommendation is based on the Phase III IMpower110 study showing that Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy If approved,...
-
Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc....
-
With eight new configurations, cobas pro® integrated solutions offers labs greater flexibility to ramp up their testing capacity to adapt to evolving testing needsThis will allow a greater number of...
-
Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had...
-
Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC)No new safety signals were identified for tominersen in the iDMC’s...